Enabling innovation in cell and gene therapy

Expertise

dna-g624eb8017_1920 gerd altmann pixabay.jpg

Development
of new Gene Therapies

Lentiviral vector production

In the news

Importance to standardize genomic data analysis in gene therapy.

Evaluation of diversity indices to estimate clonal dominance in gene therapy studies by Guillaume Corre and Anne Galy. Molecular Therapy...

International excellence in gene therapy with the biocluster GENOTHER

Mai 19, 2023 ART-TG / Inserm is proud to be part of the gene therapy biocluster GENOTHER, one of the 5 bioclusters announced by the...

ART-TG is recruiting a head for its Bioproduction unit

02 Feb 2023. ART-TG is recruiting a head for its Bioproduction unit, a great opportunity to contribute to exciting research in gene...

La Ministre de la Recherche en visite à l'ART-TG. Focus sur la Thérapie Génique.

Visite de Sylvie Retailleau, Ministre de la Recherche, de l'Enseignement Supérieur et de l'Innovatio, accompagnée de Gilles Bloch,...

Oral presentation at ESGCT 22

Presentation of poster 504 by Dr. J. Doms ART-TG at ESGCT Vaccine technologies and Infectious Diseases. Rrom Pentland 8:30-10:40 "A...

Importance of standards in gene therapy

ART-TG contributed to lentiviral standardization, improving analytical methods. Corre et al. Gene Therapy (2022) 29:536–543 #genetherapy,...

Time to Evolve: Predicting engineered T cell toxicity with next gen. models

ART-TG contributed to this recent review by Donnadieu et al. in Journal for Immunotherapy of Cancer, https://jitc.bmj.com/content/10/5/e0...

ART-TG recruits

ART-TG recruits engineers and managers for its projects. Please check the JOBS annoucements

ASMA is laureate of BPI "Grand Défi - Biomédicaments"

ASMA project: Acoustic Solutions for Manufacturing Advanced Therapies

HAPPY 2022

Visitez l'ART-TG pour la fête de la science 2021

https://www.youtube.com/watch?v=6jzlHz2Vbrw

Artificial Intelligence to improve the bioproduction of lentiviral gene therapy vectors.

ART-TG is pleased to announce its collaboration with WhiteLab Genomics on the development of artificial intelligence to improve the...

ART-TG is a partner of the IRIS network of excellence (RHU) aiming to develop new generations...

. ..of gene therapies for severe immune deficiencies. In this consortium, ART-TG will bring its expertise on the quality control of...

ART-TG joints the T2Evolve European consortium

Development of CAR-T cell therapies to fight cancer. Read the press release.

ART-TG welcomes the arrival of Gaele RIGAULT

Gaele RIGAULT has been appointed to develop the partnerships and business of MAGENTA, the industrial integrator in cell and gene therapy.

L'ART-TG vous présente ses meilleurs voeux pour 2021

Best wishes for a healthy new year 2021 and for the progress of science !

Colloque Pharmacité

Organisé par le LEEM, 3 tables rondes font le point sur les partenariats public privé. Avec la participation d'A. Galy. Les échanges...

HIV B-VAC project funded by ANRS

ART-TG and VRI teams have received 3-year funding from ANRS to develop new HIV vaccines based on CRISPR genome editing of B cells.

MAGENTA reçoit le label "Intégrateur Industriel"

ART-TG et Cithera joignent leurs expertises en thérapie cellulaire et génique pour fonder MAGENTA qui reçoit le label "Integrateur...

Presentation of ART-TG at the Mabdesign Symposium

ART-TG and MAGENTA are presented at the Bioproduction Congress organized by Mabdesign.

About us

ART-TG is an innovation and development laboratory for cell and gene therapy, established by Inserm. Its mission is to accelerate the transfer of promising research discoveries towards clinical stages, which ultimately will ensure that the best gene therapies will be available for patients.

Anne Galy, founder of ART-TG (view her bio)

ART-TG is a founding member of the MAGENTA industrial integrator, established by the French government to address the challenges of industrial production of biomedecines.